Acute Coronary Syndromes Management

Introduction to Beta-Blockade Therapy

The American College of Cardiology recommends early aggressive IV beta-blockade may increase risk of cardiogenic shock in the first 24 hours in high-risk patients, such as those with age >70 years, systolic BP <120 mmHg, heart rate >110 bpm or <60 bpm, or increased time since symptom onset 1, 2
Benefits of beta-blockade, such as reduced reinfarction and ventricular fibrillation, typically appear from Day 2 onward, as seen in the COMMIT/CCS-2 trial using metoprolol 1
The American College of Cardiology suggests avoiding IV beta-blockers in patients with signs of heart failure, evidence of low output state, increased risk for cardiogenic shock, PR interval >0.24 seconds, second or third-degree heart block, or active asthma or reactive airway disease 1

For IV administration of metoprolol, the American Heart Association recommends monitoring continuously for heart rate and blood pressure changes, ECG changes, rales, and bronchospasm 3
The American College of Cardiology recommends holding metoprolol if the heart rate is below 50 beats per minute (bpm) or if systolic blood pressure is below 100 mmHg, with a caution zone for heart rates between 45-49 bpm where administration should be delayed by 12 hours if systolic BP is above 100 mmHg 4
When transitioning patients from IV to oral metoprolol, the American College of Cardiology advises applying the same heart rate and blood pressure parameters, and considering a reduced dose when restarting after holding 4
For IV bolus administration, the European Heart Journal recommends administering slowly over 1-2 minutes and monitoring vital signs continuously 5

Beta-blocker induced bradycardia increases stroke risk, with a hazard ratio of 2.17, and clinically significant bradycardia is associated with an adjusted odds ratio for death and stroke of 2.13 (95% CI 1.37 to 3.12), according to the American College of Cardiology 4
Clinically significant hypotension is associated with an adjusted odds ratio for death and stroke of 4.97 (95% CI 3.62 to 6.81), as reported by the American College of Cardiology 4
Perioperative beta blockade is associated with increased incidence of bradycardia (OR 3.49, 95% CI 2.4 to 5.9) and congestive heart failure (OR 1.68, 95% CI 1.00 to 2.8), as stated by the American Heart Association 6

In patients with heart failure, aggressive heart rate control with metoprolol may be poorly tolerated, and the maximum tolerated dose should be carefully determined 4
When a patient on metoprolol has persistent tachycardia despite therapy, consider alternative causes such as sepsis, hypovolemia, pulmonary embolism, or anemia before increasing the dose, as suggested by the American College of Cardiology 4, 7
Continuation of beta-blocker therapy in the perioperative period is a Class I indication, but titration should maintain effective heart rate control while avoiding bradycardia and hypotension, according to the American College of Cardiology 4
An absolute mean perioperative heart rate lower than 70 bpm is associated with better outcomes, but must be balanced against the risks of excessive bradycardia, as reported by the American Heart Association 7
In patients with reactive airway disease, monitor closely for signs of bronchospasm, as metoprolol may affect pulmonary function, particularly at higher doses 8
The American College of Cardiology now recommends oral initiation of metoprolol within the first 24 hours for most patients with acute coronary syndromes, unless specific indications for IV therapy exist 3, 9